Ketamine in OCD: Efficacy and Effects on Stress and Cognition
Key facts
- Who runs it
- Medical University of Vienna
- Where
- Austria1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 60 people, planned
- Started
- 1 Oct 2022
- Planned end
- Jun 2026
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Ketamine 50 MG/ML Blinded
- Midazolam
- Ketamine 50 MG/ML Open Label
- Treatment as Usual (TAU)
- Record updated
- 25 June 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- Primary diagnosis of obsessive-compulsive disorder
- A score of 16 or higher on the Yale-Brown Obsessive Compulsive Scale and ability to provide written informed consent
- At least one previous treatment for OCD
Who cannot take part
- Current pharmacological therapy severely affecting the HPA-axis like corticosteroids or ACTH
- Any history of current or past psychotic disorder
- Any current severe personality disorder except comorbid anankastic personality disorder
- Unstable hypertension
- Any unstable cardiovascular disease
- Untreated disorders severely affecting the HPA-axis (M.Addison, M.Cushing)
- Any history of current or past psychotic disorder
- Any current severe personality disorder except comorbid anankastic personality disorder
- A manic episode within the preceding three years
- Current or unstable remitted substance abuse or dependence except nicotine
- Pregnancy or elevated risk of becoming pregnant during study duration (desire to have children) and refusal to utilize a proper method of contraception
- Morbus Raynaud
- Inability to follow the study protocol or adhere to operational requirements
- Current and unstable suicidality
- Untreated hyperthyroidism
- A manic episode within the preceding three years
- Current or unstable remitted substance abuse or dependence except nicotine
- Current and unstable suicidality
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The main goal of this trial is to demonstrate therapeutic efficacy of low dose ketamine in patients with OCD. We expect that ketamine will alleviate symptoms in the hours following application, but also - if effective - that the anti-OCD effects might last for several days after a single infusion.
The 3 groups in the trial
- KetamineExisting treatment, for comparison
Participants will undergo one infusion of ketamine as active comparator. (R,S-ketamine 50mg/ml solution for injection, dose: 0,5 mg per kg bodyweight) Both medications will be diluted in 100 ml saline and will be adjusted for infusion over 40 minutes, administered with a syringe pump.
Treatment: Ketamine 50 MG/ML Blinded and Ketamine 50 MG/ML Open Label
- MidazolamPlacebo, for comparison
Participants will undergo one infusion of midazolam as comparator. (0,045 mg/kg bodyweight) Both medications will be diluted in 100 ml saline and will be adjusted for infusion over 40 minutes, administered with a syringe pump.
- Treatment as UsualExisting treatment, for comparison
Participants will receive standard-of-care treatment-which may include psychotherapy, pharmacotherapy, physiotherapy, ergotherapy, or a combination of these-at the discretion of the treating physician, independently of the study.
Treatment: Treatment as Usual (TAU)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Ketamine Therapy in Obsessive-compulsive Disorder and Its Effects on Neuropsychological Function Under Stress in a Cross-over Trial
- Record updated
- 25 June 2025